COST EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AS TREATMENT FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER AFTER FAILURE OF DOCETAXEL USING DATA FROM REAL LIFE TREATMENT PRAXIS IN SWEDEN

被引：1
|
作者：
Persson, U. [1 ]
Nilsson, S. [2 ]
Prutz, C. [3 ]
Hjortsberg, C. [3 ]
机构：
[1] Swedish Inst Hlth Econ, Lund, Sweden
[2] Dept Oncol Pathol, Stockholm, Sweden
[3] Janssen Cilag AB, Sollentuna, Sweden
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.655
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A134 / A135
页数：2
相关论文
共 50 条
  • [41] Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
    Rauch, Simon
    Fong, Dominic
    Morra, Elisa
    Maines, Francesca
    Caffo, Orazio
    Spizzo, Gilbert
    PROSTATE INTERNATIONAL, 2016, 4 (02) : 54 - 55
  • [42] Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy
    Danila, D. C.
    Rathkopf, D. E.
    Morris, M. J.
    Slovin, S. F.
    Schwartz, L. H.
    Farmer, K.
    Anand, A.
    Haqq, C.
    Fleisher, M.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden
    Svensson, Johanna
    Andersson, Emelie
    Persson, Ulf
    Edekling, Thomas
    Ovanfors, Anna
    Ahlgren, Goran
    SCANDINAVIAN JOURNAL OF UROLOGY, 2016, 50 (04) : 286 - 291
  • [44] New treatment options in castration resistant prostate cancer: enzalutamide and abiraterone acetate
    Akdogan, Bulent
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2013, 12 (02): : 111 - 114
  • [45] Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer
    Agarwal, Neeraj
    Hutson, Thomas E.
    Vogelzang, Nicholas J.
    Sonpavde, Guru
    FUTURE ONCOLOGY, 2010, 6 (05) : 665 - 679
  • [46] Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
    Cheng, H. H.
    Gulati, R.
    Azad, A.
    Nadal, R.
    Twardowski, P.
    Vaishampayan, U. N.
    Agarwal, N.
    Heath, E. I.
    Pal, S. K.
    Rehman, H-t
    Leiter, A.
    Batten, J. A.
    Montgomery, R. B.
    Galsky, M. D.
    Antonarakis, E. S.
    Chi, K. N.
    Yu, E. Y.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2015, 18 (02) : 122 - 127
  • [47] The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
    Schweizer, Michael T.
    Zhou, Xian C.
    Wang, Hao
    Bassi, Sunakshi
    Carducci, Michael A.
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    EUROPEAN UROLOGY, 2014, 66 (04) : 646 - 652
  • [48] Enzalutamide Treatment in Metastatic Castration-resistant Prostate Cancer: Before and after Docetaxel
    Bilgetekin, Irem
    Basal, Fatma Bugdayci
    Cinkir, Havva Yesil
    Esin, Ece
    Oksuzoglu, Berna
    Demirci, Umut
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2020, 30 (08): : 815 - 821
  • [49] Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer
    Zhang, Tian
    Dhawan, Mallika S.
    Healy, Patrick
    George, Daniel J.
    Harrison, Michael R.
    Oldan, Jorge
    Chin, Bennett
    Armstrong, Andrew J.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (04) : 392 - 399
  • [50] Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect Comparison
    Tan, Pui S.
    Haaland, Benjamin
    Montero, Alberto J.
    Kyriakopoulos, Christos E.
    Lopes, Gilberto
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2014, 8 : 29 - 36
12345